These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18589368)

  • 1. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
    J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
    Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
    Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 4. [New aspects of immunotherapy of malignant melanoma].
    Enk A
    Praxis (Bern 1994); 2001 Mar; 90(10):403-6. PubMed ID: 11305186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active specific immunotherapy with vaccinia melanoma oncolysate.
    Wallack MK; Scoggin SD; Sivanandham M
    Mt Sinai J Med; 1992 May; 59(3):227-33. PubMed ID: 1318507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells as melanoma vaccines.
    Banchereau J; Fay J; Paczesny S; Ueno H; Dhodapkarz M; Palucka AK
    Dev Biol (Basel); 2004; 116():147-56; discussion 179-86. PubMed ID: 15603190
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapeutic approaches for the treatment of malignant melanoma.
    Curiel-Lewandrowski C; Atkins MB
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
    Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically modified dendritic cell-based cancer vaccines.
    Bubeník J
    Folia Biol (Praha); 2001; 47(5):153-5. PubMed ID: 11686430
    [No Abstract]   [Full Text] [Related]  

  • 11. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
    Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for melanoma.
    Weber J
    Curr Opin Oncol; 2011 Mar; 23(2):163-9. PubMed ID: 21192262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shortcomings halt study of Swiss cancer vaccine.
    Schiermeier Q
    Nature; 2003 Dec; 426(6966):484. PubMed ID: 14654802
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccine therapy for renal cancer.
    Amato RJ
    Expert Rev Vaccines; 2008 Sep; 7(7):925-35. PubMed ID: 18767943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
    Walker DG; Laherty R; Tomlinson FH; Chuah T; Schmidt C
    J Clin Neurosci; 2008 Feb; 15(2):114-21. PubMed ID: 18083572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Linear porokeratosis].
    Darrigade AS; Conte H; Ip Kan Fong H; Taïeb A; Jouary T
    Ann Dermatol Venereol; 2011 Nov; 138(11):800-2. PubMed ID: 22078049
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
    Di Nicola M; Carlo-Stella C; Anichini A; Mortarini R; Guidetti A; Tragni G; Gallino F; Del Vecchio M; Ravagnani F; Morelli D; Chaplin P; Arndtz N; Sutter G; Drexler I; Parmiani G; Cascinelli N; Gianni AM
    Hum Gene Ther; 2003 Sep; 14(14):1347-60. PubMed ID: 14503969
    [No Abstract]   [Full Text] [Related]  

  • 18. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
    Danielli R; Fonsatti E; Calabrò L; Di Giacomo AM; Maio M
    Ann N Y Acad Sci; 2012 Oct; 1270():8-12. PubMed ID: 23050811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of gangliosides in active immunotherapy with melanoma vaccine.
    Ravindranath MH; Morton DL
    Int Rev Immunol; 1991; 7(4):303-29. PubMed ID: 1779175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.